Since TLR7 was the most differently expressed TLR between SMZL and SDRPL, and since it shares the same signaling pathway as TLR9 (described by Fonte et al. [12] as having functional impact on SMZL B cells), we focused our attention on the impact of TLR7 and TLR9 agonists on these two different lymphoma entities. The gene discussed is TLR7; the disease is lymphoma.